Telefona gönder: RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY